Dupilumab treatment is not associated with changes in lymphoma risk in atopic dermatitis and other type 2 inflammatory diseases: data from a large-scale retrospective cohort study
T2IDs, including AD, are associated with a significantly increased risk for lymphoma. Treatment with dupilumab partially ameliorates this risk association, especially for NHL.
Authors
- Gema Hernandez
- Henner Zirpel (ORCID: https://orcid.org/0000-0003-0053-4312)
- Katja Bieber (ORCID: https://orcid.org/0000-0002-3855-6683)
- Nikolas C. C. von Bubnoff (ORCID: https://orcid.org/0000-0001-9593-8947)
- Henning Olbrich (ORCID: https://orcid.org/0000-0003-0863-7148)
- Dagmar von Bubnoff
- Diamant Thaçi (ORCID: https://orcid.org/0000-0001-8513-550X)
- Khalaf Kridin
- Ralf J. Ludwig
Institutions
- Bar-Ilan University (IL)
- SKiN Health (CA)
- University Hospital Schleswig-Holstein (DE)
- Centre for Inflammation Research (GB)
- Universidad Politécnica de Madrid (ES)
- University of Lübeck (DE)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2026-01-20
- DOI
- https://doi.org/10.3389/fmed.2025.1702736
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Deutsche Forschungsgemeinschaft